Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06355661

A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections

Upper Respiratory Tract Infections Clinical Trial

Official title:
A Double-blind, Randomized, Placebo-Controlled, Comparative Study for Assessing the Efficacy and Safety of ParActin® in Individuals With Upper Respiratory Tract Infections (URTI)

Clinical Trial Summary

The present study is a randomized, double-blind, placebo-controlled, comparative study. 176 individuals will be screened, and considering a screening failure rate of 15 percent approximately 150 will be randomized in a ratio of 1:1 to receive either IP or placebo and will be assigned a unique randomization code. Each group will have at least 60 completed participants after accounting for a dropout/withdrawal rate of 20percent. The intervention duration for all the study participants is 7 days

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06355661
Study type Interventional
Source Vedic Lifesciences Pvt. Ltd.
Contact Dr. Shalini Srivastava, MBBS, MD
Phone 9920789140
Email shalini.s@vediclifesciences.com
Status Not yet recruiting
Phase N/A
Start date April 10, 2024
Completion date June 1, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01158560 - A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Phase 3
Completed NCT00965822 - A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population Phase 2
Completed NCT01019889 - Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection Phase 3
Not yet recruiting NCT05484102 - Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Common Infectious Diseases in Children N/A
Recruiting NCT05804123 - LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media N/A
Terminated NCT01964885 - Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections Phase 3
Completed NCT01773824 - Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care N/A
Completed NCT01883427 - Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children Phase 2
Completed NCT01215682 - Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers N/A
Completed NCT04019730 - The Effect of a Ketogenic Diet on the Exercise Induced Immune Response N/A
Completed NCT01604096 - Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy Phase 2
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT03463694 - Edinburgh and Lothian Virus Intervention Study in Kids N/A
Completed NCT06127186 - Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections
Completed NCT03198676 - A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production Phase 1
Withdrawn NCT05557214 - Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers N/A
Completed NCT01893762 - Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes N/A
Completed NCT01129128 - Three Arm Trial of Immune Effects of Echinacea N/A
Completed NCT01396889 - Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years N/A
Completed NCT05252468 - COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19). N/A